David Gallego-Ortega , Teresa Gómez del Pulgar , Fátima Valdés-Mora , Arancha Cebrián , Juan Carlos Lacal
{"title":"人胆碱激酶α和β参与癌变:在脂质代谢和生物学功能中的不同作用","authors":"David Gallego-Ortega , Teresa Gómez del Pulgar , Fátima Valdés-Mora , Arancha Cebrián , Juan Carlos Lacal","doi":"10.1016/j.advenzreg.2010.09.010","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":7301,"journal":{"name":"Advances in enzyme regulation","volume":"51 1","pages":"Pages 183-194"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.advenzreg.2010.09.010","citationCount":"50","resultStr":"{\"title\":\"Involvement of human choline kinase alpha and beta in carcinogenesis: A different role in lipid metabolism and biological functions\",\"authors\":\"David Gallego-Ortega , Teresa Gómez del Pulgar , Fátima Valdés-Mora , Arancha Cebrián , Juan Carlos Lacal\",\"doi\":\"10.1016/j.advenzreg.2010.09.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":7301,\"journal\":{\"name\":\"Advances in enzyme regulation\",\"volume\":\"51 1\",\"pages\":\"Pages 183-194\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.advenzreg.2010.09.010\",\"citationCount\":\"50\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in enzyme regulation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0065257110000658\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in enzyme regulation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0065257110000658","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 50
摘要
我们在此总结了ChoKα1在人类癌变中的重要性。ChoKα1通过激活影响细胞增殖和存活的特定信号通路显示其致癌活性。它在大量人类肿瘤中过表达,发生率为所有研究肿瘤的40-60%。目前,人们正在积极研究通过特异性siRNA或小分子抑制剂来抑制ChoKα活性的策略。基因沉默或MN58b治疗的结果为这一概念提供了强有力的支持,MN58b是一种表征良好的ChoKα抑制剂,在小鼠异种移植物中具有抗增殖和抗肿瘤作用,表明新的抗肿瘤药物的设计必须选择性地针对这种亚型。然而,影响其他两种已知的ChoK亚型也可能具有治疗效果,因为ChoK的生理活性形式可能由同性或异源二聚体构成。此外,ChoKβ活性的改变可能导致特定组织(如骨骼肌)细胞脂质含量的变化,正如在ChoKβ缺失的小鼠中所描述的那样(Sher等,2006)。最后,鉴定ChoKα1亚型作为癌症患者诊断和预后的一种优秀的新工具可能具有立即有用的临床后果。一方面,现在可以通过标准的免疫组织化学技术,将针对ChoKα1的特异性单克隆抗体作为患者活检石蜡包埋样品的诊断工具(Gallego-Ortega et al., 2006)。另一方面,最近有研究描述了利用实时定量PCR技术检测非小细胞肺癌中ChoKα1表达水平的预后价值(Ramírez de Molina et al., 2007)。因此,应该支持进一步的研究,将ChoK异构体作为改善癌症诊断和治疗的一个有希望的领域。